Search

Learn how MSK is helping a young mother cope with rectal cancer through the Center for Young Onset Colorectal Cancer, the first program in the country devoted to younger adults with this disease.

… Thursday, June 13, 2019 MSK patient Kara Kenny hugging medical oncologist Diane Reidy Lagunes "At MSK, this proud Oklahoman learned what the phrase 'in a New York minute' really means," says Kara Kenny. "In one day, I met both my medical oncologist, Diane Reidy Lagunes, and my surgical oncologist, Martin

The genome-editing technique uncovered several genes previously not known to influence embryonic development.

… Tuesday, July 2, 2019 Summary With the help of the genome-editing tool CRISPR, developmental biologists at the Sloan Kettering Institute have uncovered a set of genes that was previously unknown to influence cell fate decisions. Life is about choices. That’s as true for cells as it is for people. Every

Meet the students who were awarded fellowships based on academic excellence for the 2020–2021 academic year.

… Thursday, September 17, 2020 Every year, the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences awards fellowships to two third-year students and six second-year students based on academic excellence. Student stipends at GSK are supported by a variety of sources, including philanthropic

The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab. MSK investigators have led much of the research that resulted in this combined drug approval.

… Friday, June 21, 2024 The US Food and Drug Administration has granted accelerated approval  for the targeted therapy  adagrasib (Krazati ® )  in combination with the drug  cetuximab (Erbitux ® )  for people with advanced  colorectal cancer  caused by a gene mutation called  KRAS -G12C. Adagrasib is the

La terapia dirigida adagrasib recibió una aprobación acelerada para el cáncer colorrectal causado por una mutación llamada KRAS-G12C, cuando se usa en combinación con el fármaco cetuximab. Los investigadores de MSK han liderado gran parte de la investigación que llevó a la aprobación de esta combinación de fármacos.

… Friday, June 21, 2024 La Administración de Alimentos y Medicamentos de los Estados Unidos ha otorgado la aprobación acelerada  para la terapia dirigida  adagrasib (Krazati ® )  en combinación con el fármaco  cetuximab (Erbitux ® )  para personas con  cáncer colorrectal  avanzado causado por una mutación

Open to patients in January 2020, the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center provides nearly every aspect of cancer care under one roof.

… Wednesday, April 1, 2020 By Jim Stallard The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center began welcoming patients for treatment on January 20, 2020. “This remarkable building creates the space, in every sense of the word, for our breakthrough research and therapies

A new treatment is approved for an especially aggressive kind of colorectal cancer.

… Wednesday, April 29, 2020 Summary People with colorectal cancer whose tumors carry a mutation called BRAF V600E have not done well under standard therapies after earlier treatments did not work. A new approach combining two targeted drugs has just been approved by the FDA after positive results in a

MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.

… Monday, February 15, 2021 Update: On August 11, 2021, the FDA approved pembrolizumab (Keytruda®) plus lenvatinib (Lenvima®) for first-line treatments for patients with advanced renal cell carcinoma (RCC). Memorial Sloan Kettering Cancer Center (MSK) physicians and scientists presented new research at

Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.

… Tuesday, October 22, 2019 Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will

Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

… Monday, April 20, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are reporting exciting results in the field of cancer immunology. Positive results from a clinical trial published today in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab